



FOR IMMEDIATE RELEASE

**Quinton Oswald Appointed Chief Executive Officer of Neurotech Pharmaceuticals  
Seasoned Executive Brings Wealth of Experience to Ophthalmic Biotechnology Pioneer,  
Including Leadership of SARcode Bioscience and Oversight of Lucentis® Launch at Genentech**

Cumberland, RI – April 11, 2014 – Neurotech Pharmaceuticals, a biotechnology company developing sight-saving therapies for retinal disease, announced today that Quinton Oswald has been appointed Chief Executive Officer, replacing Edward “Ted” Danse. Mr. Oswald is the former CEO of SARcode Bioscience Inc., which was acquired by Shire plc in 2013.

“We are delighted to welcome Quinton to Neurotech and confident that he is the ideal leader to guide our organization forward and to the next phases of development” said Jim Mazzo, Neurotech Executive Chairman. “His extensive experience will be invaluable as we take our transformational treatment for wet age-related macular degeneration (wet AMD) through clinical trials and set the stage for commercial launch.”

“On behalf of our board of directors, I also want to express our appreciation and gratitude to Ted for his years of dedicated service and stewardship at Neurotech. He has done a remarkable job of leading the organization to this critical point in our development and we are pleased that he will remain with Neurotech as a consultant to ensure a smooth transition.”

Mr. Oswald brings a wealth of relevant ophthalmic industry experience to Neurotech. As CEO of SARcode, he worked cooperatively with the U.S. FDA on a Phase 3 clinical program related to signs and symptoms of dry eye disease. He was also instrumental in negotiating the sale of SARcode to Shire, and, until recently, served as a Shire Business Unit Lead. Previously, he was Vice President & Business Unit Head for Genentech’s Tissue Growth and Repair Business, which generated over \$2.1 billion in annual sales. During his tenure at Genentech, Mr. Oswald also oversaw the highly successful commercial launch of Lucentis® (ranibizumab) for the treatment of wet AMD. Prior to Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD.

“Neurotech has developed a truly novel technology with the potential to dramatically improve the treatment of retinal diseases,” said Mr. Oswald. “I am honored to join the organization and enthusiastic about this new opportunity to combat blindness by delivering effective, leading-edge solutions to physicians, patients and payors.”

## About Neurotech Pharmaceuticals, Inc.

Neurotech is developing transformational, sight-saving therapeutics for the treatment of chronic retinal diseases. Its patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that enables continuous delivery of protein drugs directly into the vitreous of the eye. This breakthrough technology eliminates the need for monthly eye injections, overcoming a major obstacle in the treatment of retinal disease. The Company's lead ECT-based product candidates include NT503 for the treatment of wet AMD (Phase 2), and Renexus<sup>®</sup> (NT501) for the treatment of Macular Telangiectasia (prePhase 2). Neurotech's ECT systems can produce a full range of modern biotherapeutic drug classes, including peptides, hormones, monoclonal antibodies, antibody fragments and next-generation alternative scaffolds. Moreover, ECT can be easily adapted to generate protein drugs targeting uveitis, glaucoma and other ophthalmic indications. To learn more, visit [www.neurotechusa.com](http://www.neurotechusa.com).

### Contact:

Luciana Castro  
Versant Ventures  
650-233-2214  
[lcastro@versantventures.com](mailto:lcastro@versantventures.com)

###